Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort (PRESENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02356497
Recruitment Status : Recruiting
First Posted : February 5, 2015
Last Update Posted : September 25, 2019
Sponsor:
Information provided by (Responsible Party):
Helena M Verkooijen, UMC Utrecht

Brief Summary:

Bone metastases are frequent distant manifestations of cancer, with pain as a common and devastating consequence. The primary treatment for painful bone metastases, external beam radiation therapy, is moderately effective: about 60% of patients who undergo conventional radiotherapy experience (partial) pain relief. Several factors associated with treatment failure have been identified, but no attempts have been made to collapse these factors into a clinically useful prediction tool to predict treatment response. In addition, to aid in therapy selection based on expected survival time, development of survival models is essential. Finally, we need innovative treatments as alternatives or additive to standard treatment options to improve quality of life (QoL). For these reasons, we set up the PRESENT cohort study, recruiting patients at the departments of radiation oncology and orthopedic surgery.

We aim to provide detailed information about clinical data, create an infrastructure for efficient, fast and pragmatic evaluation and implementation of innovative interventions, as well as development of accurate new prediction tools.


Condition or disease
Bone Metastases

Detailed Description:
The PRESENT cohort is set up according to the 'cohort multiple Randomised Controlled Trial' design. The basis of this design is a prospective cohort of patients with bone metastases, receiving care as usual, who give informed consent for cohort participation. At the UMC Utrecht, patients are furthermore asked for informed consent to be randomized in future RCTs conducted within the cohort. Patients are informed that they will be offered the experimental intervention if they are randomly selected. They are also informed that they otherwise might serve as controls without being notified and that their data can be used in a trial context. For each patient in the cohort, clinical and patient-reported outcomes are captured at baseline and at regular intervals during follow-up. Within this cohort, multiple RCTs can be conducted. For this purpose, eligible patients who have provided the consent required for them to participate in an RCT within the cohort are identified. From this subcohort, a random selection of patients will be invited to undergo the experimental intervention. Eligible participants who were not randomly selected receive standard care, are not informed about the experimental intervention and serve as controls. Outcomes in this control group are compared with the outcomes of those who were offered the experimental intervention, in order to estimate the effect of the experimental intervention versus usual care. Within the cohort, the same process can be repeated for trials of other interventions.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort
Actual Study Start Date : June 2013
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023



Primary Outcome Measures :
  1. Pain response [ Time Frame: at 2, 4, 6, 8 weeks, 3 and 6 months, then every 6 months ]

Secondary Outcome Measures :
  1. Health-related Quality of Life [ Time Frame: at 2, 4, 6, 8 weeks and 3 months ]
  2. Toxicity according to CTCAE version 4 [ Time Frame: up to 3 months ]
    Grade 3 and 4 side effects occurring during or up to 3 months after radiotherapy will be registered according to the Common Terminology Criteria for Adverse Events (CTCAE version 4). The following side effects will be registered: Nausea; Vomiting; Diarrhoea; Pain flare.

  3. Readmission [ Time Frame: up to 3 years ]
    Reintervention (reirradiation, surgery, other); Development of neurological symptoms; Development of pathologic fracture

  4. Survival [ Time Frame: up to 3 years ]
    Survival of participating patients will be recorded using the follow up questionnaires (returned by family members) or are derived from the Municipal Personal Records Database (in Dutch: Gemeentelijke Basisadministratie, GBA).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with bone metastases undergoing radiotherapy will be asked to participate in this cohort study.
Criteria

Inclusion Criteria:

  • Histologic proof of malignancy;
  • Radiographic or histologic proof of metastatic bone disease;
  • Undergoing radiotherapy;
  • Age > 18 years;
  • Informed consent - at least - for use of routinely collected clinical data.

Exclusion Criteria:

  • Mentally incompetent patients;
  • Life expectancy < 1 week indicated by the treating physician.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02356497


Contacts
Layout table for location contacts
Contact: Joanne M. van der Velden, MD +31(0)887550803 j.m.vandervelden@umcutrecht.nl
Contact: Helena M. Verkooijen, MD, PhD h.m.verkooijen@umcutrecht.nl

Locations
Layout table for location information
Netherlands
University Medical Center Utrecht Recruiting
Utrecht, Netherlands, 3508 GA
Contact: Joanne M. van der Velden, MD    +31(0)887550803    j.m.vandervelden@umcutrecht.nl   
Contact: Helena M. Verkooijen, MD PhD       h.m.verkooijen@umcutrecht.nl   
Sponsors and Collaborators
UMC Utrecht
Investigators
Layout table for investigator information
Principal Investigator: Helena M. Verkooijen, MD, PhD UMC Utrecht
Additional Information:
Layout table for additonal information
Responsible Party: Helena M Verkooijen, Prof. dr., UMC Utrecht
ClinicalTrials.gov Identifier: NCT02356497    
Other Study ID Numbers: NL49273.041.14
First Posted: February 5, 2015    Key Record Dates
Last Update Posted: September 25, 2019
Last Verified: September 2019
Keywords provided by Helena M Verkooijen, UMC Utrecht:
Bone metastases
Metastatic bone disease
Multi-trial facility
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Bone Neoplasms
Bone Marrow Diseases
Neoplastic Processes
Neoplasms
Pathologic Processes
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Hematologic Diseases